The username/email didn't match the password, please try again!

The email you have inserted is not registered at Medicon Valley Online. If you wish to gain access to a specific organization profile please speak to one of the registered contacts of that organization. The registered contacts can usually be found on the profile page of that organization.

The email you have inserted is not in our database. Plese try again!

To add a compound to a pipeline your organisation needs to be registered as a biotech or pharmaceutical company at Medicon Valley Online. If your organisation is already registered please click on the Sign in button below. If you wish to register a new organisation, please click the Register button.

To add a service your organisation needs to be registered at Medicon Valley Online as a member of Medicon Valley Alliance and have paid the one time fee of 2300 EUR for the service section. If this has been accomplished please, just click the Sign in button below. If you want access to the services section or media about it please send your contact details to contact@mediconvalleyonline.com and we will get back to you.

Please enter your email address in the field below. Once submitted a message, with an authorization link, will be sent to this address so that you can set a new password for your account. You will have access to you account again in a couple of minutes. Thank you for your patience.

Email Print PDF Bookmark | | More

View all organisations

CytoVac A/S

Biotech Company / Biological Products

Pipeline

Staff

Contact

Member of Medicon Valley Alliance

Description

CytoVac A/S is a research and clinical development company focused on cell-based personalized therapies, aiming to provide new possibilities for treatment of serious disease, in the area of oncology and other life threatening diseases. CytoVac is in collaboration with hospitals in Denmark performing Phase I/II clinical trials of their own products for the treatment of advanced prostate cancer. CytoVac has established GMP-approved production facilities and is approved by the Danish Medicines Agency as a centre for handling and manufacturing human Cell and Tissue-based products.

Drug Pipeline

ALECSAT [Internal project]

CytoVac har gennemført en fase I klinisk afprøvning af det første produkt (ALECSAT). I protokollen (CV-001) er 13 prostatacancer patienter blevet behandlet med en helt ny cellebaseret terapi. I behandlingen fik patienterne indsprøjtet en meget stor mængde af deres egne aktiverede Cytotoksiske T celler (CTL) og NK celler, med henblik på at disse celler skal angribe patientens kræftceller. De foreløbige resultater viser ingen bivirkninger af behandlingen og der er lovende positive indikationer for en klinisk effekt. Preliminary clinical phase I/II data from 13 late stage prostate cancer patients show that the ALECSAT treatment is well tolerated and has no side effects. In most of the patients treated the ALECSAT treatment also showed indications of clinical effect. Two new clinical trials have been started in Prostate cancer and Glioblasoma to support our clinical program.